Newborn Screening for Cystic Fibrosis by Use of a Multiplex Immunoassay
Open Access
- 1 March 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 56 (3), 445-450
- https://doi.org/10.1373/clinchem.2009.132480
Abstract
Background: Since its beginnings, newborn screening for cystic fibrosis (CF) using an assay for immunoreactive trypsinogen (IRT) has been plagued by a high rate of false-positive results (screen positive, diagnosis negative), despite attempts to reduce this rate by use of altered cutoffs and second-tier DNA testing. IRT exists as 2 isoforms: IRT1 and IRT2, with IRT2 being more closely aligned with pancreatic disease, including CF. Assay standardization between programs is a continuing problem because the IRT assays currently in use variously recognize either 1 or both isoforms. Here we report the development of a multiplexed assay for both forms of IRT simultaneously. Methods: Using 2 different Luminex bead sets, we developed assays for each IRT isoform separately and then combined them. Using the sum of IRT1 and IRT2 values (IRT1+IRT2), we compared the results with a CF kit currently in use. Results: In a sample set consisting of 16 cases confirmed positive for CF, we established a cutoff at >97 μg/L total IRT. Seven of 8 carriers with 1 CF mutation screen-positive by the standard method were also screen-positive by IRT1+IRT2. Of 32 cases screen-positive by standard IRT, 11 were screen-negative by IRT1+IRT2. None of these 11 cases had CF mutations identified by the screening program. Conclusions: These data indicate that the multiplex method with specificity for 2 isoforms of IRT has performance comparable to that of a standard IRT method and the advantage of improved standardization by detection of the 2 isoforms.Keywords
Funding Information
- NIH (ADB-NO1-DK-6-3430, HHSN267200603430)
This publication has 18 references indexed in Scilit:
- Newborn screening for cystic fibrosis: Techniques and strategiesJournal of Inherited Metabolic Disease, 2007
- Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newbornsActa Paediatrica, 2007
- Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogenJournal of Medical Screening, 2006
- Combining Immunoreactive Trypsinogen and Pancreatitis-Associated Protein Assays, a Method of Newborn Screening for Cystic Fibrosis that Avoids DNA AnalysisThe Journal of Pediatrics, 2005
- Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non‐carriersAmerican Journal of Medical Genetics Part A, 2005
- Evaluation of the Quantase™ neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosiscclm, 2005
- Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newbornsActa Paediatrica, 1999
- An evaluation of an enzyme immunoassay method for immunoreactive trypsin in dried blood spotsClinical Biochemistry, 1990
- DRIED-BLOOD SPOT SCREENING FOR CYSTIC FIBROSIS IN THE NEWBORNThe Lancet, 1979
- Two human trypsinogens. Purification, molecular properties, and N-terminal sequencesBiochemistry, 1978